期刊文献+

还原型谷胱甘肽联合辛伐他汀治疗非酒精性脂肪性肝炎 被引量:9

Reduced Glutathione Combined with Simvastatin in the Treatment of Non-alcoholic Steatohepatitis
下载PDF
导出
摘要 目的:观察还原型谷胱甘肽联合辛伐他汀治疗非酒精性脂肪性肝炎的临床疗效。方法:86例非酒精性脂肪性肝炎患者随机分为两组,对照组给予饮食控制,同时口服辛伐他汀5 mg,po,qn;治疗组在对照组基础上加用还原型谷胱甘肽1.8g,ivd,qd,两组疗程均为4周。结果:治疗组总有效率88.64%,明显高于对照组总有效率(61.90%)(P<0.05)。各组治疗后ALT及血清胆固醇、血清甘油三酯明显降低(P<0.01)。与对照组比较,治疗组治疗后ALT明显降低(P<0.05),血清胆固醇及血清甘油三酯差异无统计学意义(P>0.05)。结论:还原型谷胱甘肽联合辛伐他汀治疗非酒精性脂肪性肝炎能有效降低血清ALT水平,疗效明显优于单用辛伐他汀。 Objective: To observe the clinic curative effect of reduced glutathione combined with simvastatin in the treatment of non-alcoholic steatohepatitis. Method: Eighty-six patients with non-alcoholic steatohepatitis were randomy divided into treatment group and control group. The control group were given a controlled diet and oral simvastatin 5 mg qn. Based on the control group, the treatment group were given intravenous reduced glutathione 1.8 g, qd. as well. Both course of the treatment of the 2 groups were 4 weeks. Result: The total effective rate of the treatment and control group was 88. 64% and 61.90% , respectively , the differences were statistically significant (P 〈 0.05 ). After treatment, compared with the control group, ALT levels of patients in the treatment group was decreased significantly, the differences were statistically significant ( P 〈 0. 05 ), But serum cholesterol and serum triglyceride differences of the 2 groups were not statistically significant (P 〉 0. 05). In both group, ALT, serum cholesterol and serum triglyceride levels were all decreased significantly (P 〈 0. 01 ). Conclusion: Treatment of non-alcoholic steatohepatitis using reduced glutathione combined with simvastatin effectively decreased serum ALT and it's obviously better than using simvastatin alone.
出处 《中国药师》 CAS 2010年第8期1161-1163,共3页 China Pharmacist
关键词 还原型谷胱甘肽 脂肪性肝炎 非酒精性 辛伐他汀 Reduced glutathione Steatohepatitis Non-alcoholic Simvastatin
  • 相关文献

参考文献10

二级参考文献18

  • 1Arun A. T Gastroenterology, 2002,123(2) : 1705 - 1725.
  • 2Yamauchi, Kamon, WakiH, et al. Nat med, 2001 , 7(4): 941-946.
  • 3UyqumA, kadayifci A, Yesilova I, et al. AmJ Gastroenterol,2000,95(5) :3584-3589.
  • 4Lin H, Yang S, Chuckaree C,et al. Nat reed, 2000,6(2):998-1003.
  • 5Giulio M, Mara B, Giampalo B, et al. Lancet,2001,358(3):893-894.
  • 6Caldwell SH, Hespenheide EE, Redick JA, et al. AmJ Gastroen-terol, 2000 , 96(3): 519- 525.
  • 7MayLD, Lefkowitch JH, kram MT, et al. Ann Intern reed, 2002,136(4) :449-452.
  • 8Yang WS,.leng CY, Wu T.I, et al. Diabetes Care, 2002 ,25(6):376-380.
  • 9Laurin, lindor KD, Crippin J, et al. A pilot study. 2001 ,24(3):256-258.
  • 10Basaranoglu M, Aebay O, Sosuz A. J Hepatol, 1999 ; 31 (4) : 384-386.

共引文献1528

同被引文献71

引证文献9

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部